Encysive Pharmaceuticals Inc

Encysive Pharmaceuticals — ThinkEquity Partners 4th Annual Growth Conference 2006

25 slides from Encysive Pharmaceuticals's conference presentation, Sep 11, 2006

  1. Slide 1: ThinkEquity Partners 4th Annual Growth Conference

    Slide 1: ThinkEquity Partners 4th Annual Growth Conference

    ThinkEquity Partners 4th Annual Growth Conference September 11, 2006

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends an

  3. Slide 3: Overview

    Slide 3: Overview

    Overview Encysive is engaged in the development and commercialization of novel, synthetic, small molecule compounds in the area of vascular biology Company headquarters in Houston; European operations (Encysive UK Ltd) based outside London First product (Argatroban) approved and marketed by GlaxoSmi

  4. Slide 4: Investment Highlights

    Slide 4: Investment Highlights

    Investment Highlights In August 2006 THELIN(r) (sitaxentan sodium) 100 mg tablets approved for treatment of PAH in all 25 countries of European Union

  5. Slide 5: Investment Highlights

    Slide 5: Investment Highlights

    Investment Highlights 3 additional regulatory reviews pending for THELIN(tm) US FDA "approvable letter" Australia (priority review) Canada Commercial organization in place in both United States and Europe Attractive product opportunity ENCY owns 100% of worldwide THELIN revenues Efficient market, pr

  6. Slide 6: Pulmonary Arterial Hypertension (PAH)

    Slide 6: Pulmonary Arterial Hypertension (PAH)

    Pulmonary Arterial Hypertension (PAH) Rare, life-threatening condition causing high blood pressure in the lungs due to narrowing and stiffening of pulmonary arteries Symptoms include shortness of breath, fatigue, dizzy spells, fainting, chest pain, and swelling of ankles and legs PAH may develop wit

  7. Slide 7: PAH - A Growing Market Opportunity

    Slide 7: PAH - A Growing Market Opportunity

    PAH - A Growing Market Opportunity... Estimated 100,000 - 200,000 patients in North America and Europe Market still growing rapidly Physician awareness continues to grow More than $500MM in ETRA product sales in NA and EU in 2005 with double digit growth New entrant can fuel growth Rate of diagnosis

  8. Slide 8: Diagnosed PAH Patients Projected to Double by 2009

    Slide 8: Diagnosed PAH Patients Projected to Double by 2009

    Diagnosed PAH Patients Projected to Double by 2009... Source: Encysive Internal Market Model, 2005

  9. Slide 9: Basis for Regulatory Submissions

    Slide 9: Basis for Regulatory Submissions

    Basis for Regulatory Submissions Two successful pivotal trials completed (STRIDE-1, STRIDE-2) More than 1,000 PAH patients treated with THELIN(tm) in clinical studies

  10. Slide 10: STRIDE-1: Efficacy

    Slide 10: STRIDE-1: Efficacy

    STRIDE-1: Efficacy At 12 weeks, THELIN(tm) 100 mg (vs. placebo) improved: 6MW distance (placebo-corrected 35 m, p < 0.01) WHO FC (29% improved, p < 0.02) Hemodynamics PVR decreased 221 dyn/sec/cm-5 (p < 0.001) CI increased 0.3 L/min/m2 (p < 0.02) TRA06069 04.20.06 Barst RJ, et al. Am J Respir Crit C

  11. Slide 11: STRIDE-2: Efficacy

    Slide 11: STRIDE-2: Efficacy

    STRIDE-2: Efficacy Treatment with THELIN(tm) 100 mg (vs. placebo) at 18 weeks: Increased 6MW distance: treatment effect 31.4 m (p= 0.03) Improved WHO functional class: 98% improved or unchanged (p= 0.04) Barst RJ, et al. J Am Coll Cardiol. 2006;47:2049-2056

  12. Slide 12: THELIN Safety and Tolerability

    Slide 12: THELIN Safety and Tolerability

    THELIN(tm) Safety and Tolerability Favorable liver function test (LFT) elevations* STRIDE-1 (12 Weeks) 0% for THELIN 100 mg 3% for Placebo STRIDE-2 (18 Weeks) 3% for THELIN 100 mg 6% for Placebo 11% for Tracleer(r) Class effect seen with THELIN, Tracleer and ambrisentan * Single elevation greater th

  13. Slide 13: THELIN Safety and Tolerability

    Slide 13: THELIN Safety and Tolerability

    THELIN(tm) Safety and Tolerability Adverse events typical for vasodilators E.g.: Headache, nasal congestion, nausea, edema Well-characterized interaction with warfarin Handled by dose adjustment Warfarin requires close monitoring irrespective of treatment selection Monthly liver and pregnancy* testi

  14. Slide 14: THELIN Approved in the EU

    Slide 14: THELIN Approved in the EU

    THELIN(r) Approved in the EU Approved in August 2006 for marketing in all 25 EU countries THELIN 100 mg indicated for the treatment of patients with PAH classified as World Health Organization functional class III, to improve exercise capacity. Efficacy has been shown in primary (idiopathic) pulmona

  15. Slide 15: THELIN in EU: A 2nd Generation ETRA with Competitive Advantages

    Slide 15: THELIN in EU: A 2nd Generation ETRA with Competitive Advantages

    THELIN(r) in EU: A 2nd Generation ETRA with Competitive Advantages Once-daily oral tablet Lower rate of liver function test elevations Efficacy demonstrated in PAH associated with CTD No clinically meaningful interaction with sildenafil Only highly selective ETRA for PAH Only ETRA with comparator da

  16. Slide 16: EU Operations

    Slide 16: EU Operations

    EU Operations Established European HQ in UK EU operations headed by Thierry Plouvier, M.D. Country managers in place for France, Germany & UK Approximately 35 sales reps. planned for Europe UK sales organization on board and trained Germany recruiting for 4Q launch

  17. Slide 17: EU Sales Roll-Out

    Slide 17: EU Sales Roll-Out

    EU Sales Roll-Out First launch countries, UK and Germany, targeted for Q4 2006 Additional key countries targeted for 2007 launch Spain France Italy Netherlands

  18. Slide 18: Ready to Launch in the US

    Slide 18: Ready to Launch in the US

    Ready to Launch in the US 52 sales representatives trained, ready-to-go Average 11 years pharmaceutical sales experience Initial comments received from FDA on ENCY's plans for its risk map Managed care team in place Top 50 payers targeted

  19. Slide 19: US Regulatory Status

    Slide 19: US Regulatory Status

    US Regulatory Status Second FDA "approvable letter" for THELIN(tm) received on July 24 ENCY is working diligently with FDA Constructive dialogue (oral, written and face-to-face) We remain hopeful that we can resolve the remaining item without additional clinical work, discussions are ongoing

  20. Slide 20: Pipeline Chart

    Slide 20: Pipeline Chart

    Pipeline Chart PROPRIETARY PRODUCTS Thelin(tm) Oral Thelin(tm) Oral- US PC1 Oral PC2 Oral PC3 Intravenous PAH Undisclosed ILD Thelin(tm) Oral Undisclosed Undisclosed TBC3711 Oral* Thelin(tm) Intravenous TBC3711 Intravenous* Undisclosed Undisclosed Undisclosed Resistant HTN Undisclosed PARTNERED PROD

  21. Slide 21: Senior Management Team with Significant Global Pharmaceutical Experience

    Slide 21: Senior Management Team with Significant Global Pharmaceutical Experience

    Senior Management Team with Significant Global Pharmaceutical Experience... Bruce Given, M.D. President and CEO Formerly President, International of Ortho - -Clinical Diagnostics a Johnson & Johnson Company George Cole COO Formerly President of Altana Pharma U.S. Richard Dixon, Ph.D. CSO Formerly Di

  22. Slide 22: Summary

    Slide 22: Summary

    Summary 1 product approved, and 1 "approvable" in US 1 product approved in European Union EU product revenues expected to begin in Q4 2006 3 active regulatory filings Commercially ready for US launch Argatroban royalty income continues to grow Additional indications for THELIN(tm) in clinical develo

  23. Slide 23: Second Quarter 2006 Financial Results

    Slide 23: Second Quarter 2006 Financial Results

    Second Quarter 2006 Financial Results $ millions Revenue Net loss $3.7 ($28.0) Cash & investments at June 30, 2006 $75.4

  24. Slide 24: Forward-Looking Statements

    Slide 24: Forward-Looking Statements

    Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends an

  25. Slide 25: ThinkEquity Partners 4th Annual Growth Conference

    Slide 25: ThinkEquity Partners 4th Annual Growth Conference

    ThinkEquity Partners 4th Annual Growth Conference September 11, 2006

Source: SEC EDGAR · 8-K filed Sep 11, 2006

More decks from Encysive Pharmaceuticals Inc